Sensorion SAS (FR:ALSEN)
:ALSEN
Want to see FR:ALSEN full AI Analyst Report?
ALSEN Stock Chart & Stats
€0.40
€0.00(0.00%)
At close: 4:00 PM EST
€0.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.26 - €0.81
Previous CloseN/A
Volume61.80K
Average Volume (3M)540.27K
Market Cap
€143.36M
Enterprise Value€103.27M
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.23M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding514,946,960
10 Day Avg. Volume740,129
30 Day Avg. Volume540,266
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€18.88M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityModest debt and low leverage give Sensorion structural flexibility to fund R&D and negotiate deal terms without a heavy interest burden. Over a 2–6 month horizon this reduces bankruptcy risk versus highly leveraged peers and supports continued program development and partner negotiations.
Collaboration And Licensing Business ModelA partner/licensing-focused model is durable for clinical-stage biotech: it lowers commercialization capex needs, enables milestone and upfront payments, and attracts strategic partners who can fund late-stage costs. This structural model can de-risk development spending versus sole internal commercialization.
Focused Clinical-stage SpecializationConcentrating on inner ear disorders creates a differentiated niche and technical expertise that can yield a competitive moat in a specialized therapeutic area. That focus supports targeted trial designs, clearer comparator benchmarks, and potential attractiveness to partners seeking audiology/vestibular assets.
Bears Say
Sustained Negative Cash GenerationLarge, persistent operating and free cash outflows indicate ongoing burn to support trials and R&D. Over months this elevates financing risk, forces periodic capital raises or partner deals, and can constrain program continuity or timing if new funding is delayed or terms worsen.
Revenue Disruption And Sizable LossesA drop to zero revenue in 2025 combined with large operating losses signals loss of contributory income and limited internal cash offsets. Structurally this weakens the firm's ability to self-fund development, increases dependency on external financing, and lengthens time to sustainable profitability.
Dependence On External Financing And Equity VolatilityFalling equity and negative ROE reflect dilution or accumulated losses, underscoring reliance on capital markets. This structural dependence increases execution risk: future trials and milestones may hinge on raises or partner deals that dilute shareholders and constrain long-term strategic independence.
Sensorion SAS News
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.26 and its highest was €0.81 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €143.36M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 102 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.03.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 514,946,960 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -12.651%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
ALSEN Stock 12 Month Forecast
Average Price Target
€1.00
▲(150.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---